Search Results - "SCHÜTZ, Manuela"

FTY720 (fingolimod) in renal transplantation by Budde, Klemens, Schütz, Manuela, Glander, Petra, Peters, Harm, Waiser, Johannes, Liefeldt, Lutz, Neumayer, Hans-H, Böhler, Torsten

“…:  FTY720 (Fingolimod) is a novel immunomodulator with a mode of action that is completely different from classical immunosuppressants. FTY is a structural and…”
Get full text

Limitations of C2 monitoring in renal transplant recipients by Einecke, Gunilla, Schütz, Manuela, Mai, Ingrid, Fritsche, Lutz, Giessing, Markus, Glander, Petra, Neumayer, Hans-H., Budde, Klemens

“…Background. Recent developments have proposed the cyclosporin (CsA) concentration at 2 h post-dose (C2) as the best single time-point predictor of the extent…”
Get full text

Matricellular protein SPARCL1 regulates tumor microenvironment-dependent endothelial cell heterogeneity in colorectal carcinoma by Naschberger, Elisabeth, Liebl, Andrea, Schellerer, Vera S, Schütz, Manuela, Britzen-Laurent, Nathalie, Kölbel, Patrick, Schaal, Ute, Haep, Lisa, Regensburger, Daniela, Wittmann, Thomas, Klein-Hitpass, Ludger, Rau, Tilman T, Dietel, Barbara, Méniel, Valérie S, Clarke, Alan R, Merkel, Susanne, Croner, Roland S, Hohenberger, Werner, Stürzl, Michael

“…Different tumor microenvironments (TMEs) induce stromal cell plasticity that affects tumorigenesis. The impact of TME-dependent heterogeneity of tumor…”
Get full text

Comparison between bortezomib and rituximab in the treatment of antibody-mediated renal allograft rejection by WAISER, Johannes, BUDDE, Klemens, SCHÜTZ, Manuela, LIEFELDT, Lutz, RUDOLPH, Birgit, SCHÖNEMANN, Constanze, NEUMAYER, Hans-H, LACHMANN, Nils

“…Antibody-mediated rejection (ABMR) following kidney transplantation is associated with poor allograft survival. Conventional treatment based on plasmapheresis…”
Get full text

Abstract 3369: Tumor-microenvironment-dependent imprinting of endothelial cells in human colorectal carcinoma by Stürzl, Michael, Liebl, Andrea, Schellerer, Vera S., Schütz, Manuela, Kölbel, Patrick, Schaal, Ute, Haep, Lisa, Klein-Hitpass, Ludger, Rau, Timan T., Dietel, Barbara, Meniel, Valerie, Clarke, Alan R., Merkel, Susanne, Croner, Roland S., Hohenberger, Werner, Naschberger, Elisabeth

“…Abstract The tumor microenvironment (TME) and tumor cell heterogeneity contribute significantly to tumor pathogenesis. In contrast, potential stromal cell…”
Get full text

Antihumoral rejection therapy by proteasome inhibitor bortezomib: a case series by Lachmann, Nils, Schütz, Manuela, Budde, Klemens, Schönemann, Constanze, Waiser, Johannes

“…These three case reports strongly support previously published data on the usefulness of bortezomib as an innovative and potent antihumoral rejection…”
Get more information

Differential effects of single dose FTY720 on CD62L+ B-cells in stable renal allograft recipients by Böhler, Torsten, Schütz, Manuela, Budde, Klemens, Neumayer, Hans-H., Waiser, Johannes

“…FTY720, a sphingosine-1-phosphate receptor agonist, is the archeotype of a new class of immune modulators, which redirects lymphocytes from the peripheral…”
Get full text

FTY720 mediates apoptosis-independent lymphopenia in human renal allograft recipients: Different effects on CD62L+ and CCR5+ t lymphocytes by BOHLER, Torsten, WAISER, Johannes, SCHÜTZ, Manuela, DRAGUN, Duska, NEUMAYER, Hans-H, BUDDE, Klemens

“…The sphingolipid FTY720 (FTY), a novel immune modulator, induces lymphopenia and prevents allograft rejection. This study was designed to study the effect of…”
Get full text

FTY720 (fingolimod) in renal transplantation: Innovations in transplantation medicine by BUDDE, Klemens, SCHÜTZ, Manuela, GLANDER, Petra, PETERS, Harm, WAISER, Johannes, LIEFELDT, Lutz, NEUMAYER, Hans-H, BÖHLER, Torsten

Get full text